HUTCHMED H2 Earnings Call Highlights

HUTCHMED (NASDAQ: HCM) management used its 2025 annual results call to highlight growth in global sales for FRUZAQLA, a rebound in China market performance in the second half, and increasing investment behind its ATTC (antibody-targeted therapy conjugate) platform as it advances multiple assets into clinical development. 2025 highlights: overseas growth for FRUZAQLA and a second-half rebound